Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...
Argus has recently raised AbbVie Inc (ABBV) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on October 17, 2024, Bernstein had initiated the stock to Mkt Perform, ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...
Roopal Thakkar; Executive Vice President, Research & Development and Chief Scientific Officer; AbbVie Inc Scott Reents; Chief Financial Officer, Executive Vice President; AbbVie Inc Good morning ...
Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...
With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...
Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...
Shares of AbbVie Inc. ABBV shed 1.51% to $200.47 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.28% to 5,712.69 and Dow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback